Europe Antibody Drug Conjugates Market
The Europe Antibody Drug Conjugates Market size was valued at US$ 2,263.14 Mn in 2022 and is projected to reach US$ 7,947.86 Mn by 2030, growing at a CAGR of 17.0% during 2022 - 2030.
Report Coverage
- Technology: Cleavable Linker, Non-cleavable Linker
- Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
US$ 2,263.14 Mn
Market size in 2022
US$ 7,947.86 Mn
Market Size by 2030
17.0%
CAGR, 2022 - 2030
2023-2030
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Antibody Drug Conjugates Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Antibody Drug Conjugates Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Antibody Drug Conjugates Market Regional Analysis
6.2 Europe Antibody Drug Conjugates Market Revenue 2020-2030 (US$ Million)
6.3 Europe Antibody Drug Conjugates Market Forecast Analysis
7. Europe Antibody Drug Conjugates Market Analysis – by Technology
7.1 Cleavable Linker
- 7.1.1 Overview
- 7.1.2 Cleavable Linker: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Non-cleavable Linker
- 7.2.1 Overview
- 7.2.2 Non-cleavable Linker: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. Europe Antibody Drug Conjugates Market Analysis – by Application
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Breast Cancer
- 8.2.1 Overview
- 8.2.2 Breast Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.3 Ovarian Cancer
- 8.3.1 Overview
- 8.3.2 Ovarian Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.4 Urothelial Cancer
- 8.4.1 Overview
- 8.4.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. Europe Antibody Drug Conjugates Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies : Europe Antibody Drug Conjugates Market – Revenue and Forecast, 2020-2030 (US$ Million)
10. Europe Antibody Drug Conjugates Market – Europe Analysis
10.1 Overview
10.2 Europe- 10.2.1 Europe Antibody Drug Conjugates Market Breakdown, by Key Country, 2023 and 2030 (%)
- 10.2.1.1 Europe Antibody Drug Conjugates Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 UK: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.1.1 UK: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.1.2 UK: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.1.3 UK: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.2 Germany: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.2.1 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.2.2 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.2.3 Germany: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.3 France: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.3.1 France: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.3.2 France: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.3.3 France: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.4 Russia: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.4.1 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.4.2 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.4.3 Russia: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.5 Italy: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.5.1 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.5.2 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.5.3 Italy: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
- 10.2.1.6 Rest of Europe: Europe Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Technology
- 10.2.1.6.2 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Application
- 10.2.1.6.3 Rest of Europe: Europe Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 ADC Therapeutics SA
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Hoffmann-La Roche Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 ImmunoGen, Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 GSK Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Gilead Sciences Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AstraZeneca Plc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Astellas Pharma Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Takeda Pharmaceutical Co Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full E Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
